Eli Lilly Raises 2026 Revenue Guidance Amid Strong Q1 Performance
Eli Lilly reported a strong first-quarter performance in 2026, driven by high demand for its obesity and diabetes drugs. The company raised its full-year revenue guidance to between $82 billion and $85 billion.
Tickers: $LLY
Topics: Earnings Guidance GLP-1RA Drugs Obesity Treatments Pharmaceuticals Revenue Growth